April 11, 2022 -- Oxford BioTherapeutics will present preliminary clinical data from its ongoing expansion phase I trial of its experimental CD205-directed antibody drug conjugate (ADC), OBT076, on April 11 at the American Association of Cancer Research (AACR) Annual Meeting.
Oxford's summary of the presentation states that OBT076 (NCT04064359) (2-5 cycles) in combination with a checkpoint inhibitor (CPI) (1-2 cycles) showed near complete responses in low programmed cell death ligand 1 refractory solid tumor patients. Patients treated with the combination also showed tumor shrinkage, immune response, and a decrease of metastasis. The combination synergizes through a potentially novel mechanism: drug-induced depletion of CD205+ immuno-suppressive cells and subsequent T-cell activation.
Based on this preliminary data, Oxford will advance OBT076 into single agent and combination trials (with CPIs) in both checkpoint-naïve and resistant patients, according to the summary.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
